Stockscreener 앱 받기
1.52
2.70%
0.04
시장 영업 전:
1.62
0.10
+6.58%
Biomea Fusion Inc 주식(BMEA)의 최신 뉴스
Biomea Fusion to present new icovamenib data at American Diabetes Association event - Traders Union
Biomea Fusion Announces Late-Breaking Poster Presentations on Icovamenib at ADA 86th Scientific Sessions - Quiver Quantitative
Three diabetes studies put Biomea's icovamenib in ADA late-breakers - Stock Titan
Biomea Fusion Announces Poster Presentations of Icovamenib - GlobeNewswire
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions - GlobeNewswire Inc.
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026 - Yahoo Finance
Citizens initiates Biomea Fusion stock coverage citing diabetes treatment potential - Investing.com
Biomea Fusion Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
BMEA Forecast, Price Target & Analyst Ratings | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib - MarketBeat
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 DiabetesSlideshow (NASDAQ:BMEA) 2026-04-28 - Seeking Alpha
Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital - MarketBeat
Biomea Fusion Reports Positive Phase 2 T1D Trial Results - TipRanks
Biomea Fusion | 8-K: Current report - Moomoo
Phase 2 icovamenib T1D data from Biomea Fusion (NASDAQ: BMEA) show 52% C-peptide gain - Stock Titan
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment - markets.businessinsider.com
Biomea reports positive type 1 diabetes trial results By Investing.com - Investing.com South Africa
Biomea reports positive type 1 diabetes trial results - Investing.com UK
Biomea Fusion reports 52 percent C peptide AUC gain in Phase 2 diabetes trial at week 12 - Traders Union
Biomea Fusion | DEF 14A: Definitive information statements - Moomoo
Biomea Fusion Reports Promising 52-Week Results for Icovamenib in Phase 2 Trial for Type 1 Diabetes - Quiver Quantitative
In a small T1D trial, 12 weeks of treatment preserved C-peptide for 52 weeks - Stock Titan
Biomea Fusion (NASDAQ: BMEA) sets 2026 virtual meeting, director votes and Deloitte audit - Stock Titan
[ARS] Biomea Fusion, Inc. SEC Filing - Stock Titan
Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment - marketscreener.com
Biomea Fusion to Attend H.C. Wainwright Global Investment Conference - Sangri Today
Biomea Fusion announces pricing of public offering of securities - MSN
Biomea (BMEA) Stock Prediction: What’s Next After Recent Move | Q4 2025: Profit SurprisesRating Downgrade - Cổng thông tin điện tử Tỉnh Sơn La
Biomea Fusion, Inc. Common Stock (BMEA) Stock Price Today & Analysis - Gotrade
BMEA Technical Analysis | Trend, Signals & Chart Patterns | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
BMEA Should I Buy - Intellectia AI
BMEA.O PE Ratio & Valuation, Is BMEA.O Overvalued - Intellectia AI
BMEA.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BMEA.O Technical Analysis & Stock Price Forecast - Intellectia AI
BMEA News & Events - Intellectia AI
BMEA.O Forecast — Price Prediction for 2026. Should I Buy BMEA.O? - Intellectia AI
Biomea (BMEA) Stock Index Trade (Smart Money Flows) 2026-04-15Trader Community Insights - Xã Thanh Hà
COVALENT-212 study enrolls participants for icovamenib diabetes research, Biomea Fusion initiates - Traders Union
Biomea Fusion warns diabetes remains poorly controlled despite standard therapies - Traders Union
Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes - TipRanks
BMEA: Analyst Rating Maintained at Buy with Price Target Unchang - GuruFocus
Is Biomea (BMEA) Stock Breaking Resistance | BMEA Q4 Earnings: Beats Estimates by $0.53Community Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion (BMEA) awards 452,512 stock options to director and officer Erdtmann - Stock Titan
Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike - Stock Titan
Icovamenib development timeline includes Phase II updates and 52-week data in 2026 - Traders Union
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - Investing News Network
BMEA Technical Analysis & Stock Price Forecast - Intellectia AI
Biomea Fusion Announces Initiation of Phase II Trials COVALENT-211 and COVALENT-212 for Icovamenib in Type 2 Diabetes Patients - Quiver Quantitative
Biomea Fusion Announces First Patient Dosed in Newly - GlobeNewswire
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts - MarketBeat
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes - MarketBeat
0.14%
0.48%
자본화:
|
볼륨(24시간):